- Home
- SRG vs ASMB Comparison
SRG vs ASMB Comparison
Compare SRG & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- ASMB
- Stock Information
- Founded
- SRG 2014
- ASMB 2005
- Country
- SRG United States
- ASMB United States
- Employees
- SRG N/A
- ASMB 73
- Industry
- SRG Real Estate Investment Trusts
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- ASMB Health Care
- Exchange
- SRG Nasdaq
- ASMB Nasdaq
- Market Cap
- SRG 237.7M
- ASMB 225.9M
- IPO Year
- SRG 2015
- ASMB 2010
- Fundamental
- Price
- SRG $4.06
- ASMB $29.60
- Analyst Decision
- SRG
- ASMB Strong Buy
- Analyst Count
- SRG 0
- ASMB 5
- Target Price
- SRG N/A
- ASMB $44.25
- AVG Volume (30 Days)
- SRG 96.5K
- ASMB 154.9K
- Earning Date
- SRG 11-11-2025
- ASMB 11-06-2025
- Dividend Yield
- SRG N/A
- ASMB N/A
- EPS Growth
- SRG N/A
- ASMB N/A
- EPS
- SRG N/A
- ASMB N/A
- Revenue
- SRG $15,346,000.00
- ASMB $33,247,000.00
- Revenue This Year
- SRG N/A
- ASMB $14.32
- Revenue Next Year
- SRG N/A
- ASMB N/A
- P/E Ratio
- SRG N/A
- ASMB N/A
- Revenue Growth
- SRG N/A
- ASMB 54.77
- 52 Week Low
- SRG $2.43
- ASMB $7.75
- 52 Week High
- SRG $4.72
- ASMB $30.20
- Technical
- Relative Strength Index (RSI)
- SRG 51.89
- ASMB 70.92
- Support Level
- SRG $3.88
- ASMB $23.21
- Resistance Level
- SRG $4.21
- ASMB $29.20
- Average True Range (ATR)
- SRG 0.17
- ASMB 1.68
- MACD
- SRG -0.04
- ASMB 0.46
- Stochastic Oscillator
- SRG 41.94
- ASMB 92.59
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.